305 related articles for article (PubMed ID: 9829150)
1. Liposomal drug formulations. Rationale for development and what we can expect for the future.
Allen TM
Drugs; 1998 Nov; 56(5):747-56. PubMed ID: 9829150
[TBL] [Abstract][Full Text] [Related]
2. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
4. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration.
Decker C; Schubert H; May S; Fahr A
J Control Release; 2013 Mar; 166(3):277-85. PubMed ID: 23313962
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
7. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
Angst MS; Drover DR
Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
[TBL] [Abstract][Full Text] [Related]
9. Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay.
Hinna AH; Hupfeld S; Kuntsche J; Bauer-Brandl A; Brandl M
J Control Release; 2016 Jun; 232():228-37. PubMed ID: 27112112
[TBL] [Abstract][Full Text] [Related]
10. Liposomes. Opportunities in drug delivery.
Allen TM
Drugs; 1997; 54 Suppl 4():8-14. PubMed ID: 9361956
[TBL] [Abstract][Full Text] [Related]
11. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery.
Eloy JO; Claro de Souza M; Petrilli R; Barcellos JP; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2014 Nov; 123():345-63. PubMed ID: 25280609
[TBL] [Abstract][Full Text] [Related]
12. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs.
Reddy KR
Ann Pharmacother; 2000; 34(7-8):915-23. PubMed ID: 10928404
[TBL] [Abstract][Full Text] [Related]
14. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
Immordino ML; Dosio F; Cattel L
Int J Nanomedicine; 2006; 1(3):297-315. PubMed ID: 17717971
[TBL] [Abstract][Full Text] [Related]
15. Ligation strategies for targeting liposomal nanocarriers.
Marqués-Gallego P; de Kroon AI
Biomed Res Int; 2014; 2014():129458. PubMed ID: 25126543
[TBL] [Abstract][Full Text] [Related]
16. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.
Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H
Int J Pharm; 2016 May; 505(1-2):139-46. PubMed ID: 27012982
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
Drummond DC; Noble CO; Hayes ME; Park JW; Kirpotin DB
J Pharm Sci; 2008 Nov; 97(11):4696-740. PubMed ID: 18351638
[TBL] [Abstract][Full Text] [Related]
19. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
